On 6/12/24, Editas Medicine Inc (NASDAQ: EDIT) stock enjoyed a major increase of 11.2%, closing at $6.04. Moreover, this advance was accompanied by unusually high trading volume at 176% of normal. Relative to the market the stock has been extremely weak over the last nine months but has risen 5.0% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, EDIT is expected to continue to be Value Creation neutral.
Editas Medicine has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing highly consistent signals. Editas Medicine has a poor Power Rating of 25 and a poor Appreciation Score of 25, resulting in the Lowest Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment